Martin Bonde

Martin Bonde is an experienced leader in the biotechnology sector, currently serving as a Venture Partner at BiOrigin since May 2024 and as CEO and Chairman of the Board at Asgard Therapeutics since June 2022. Bonde holds board positions at Inthera Bioscience AG, BioInnovation Institute, and Visiopharm, showcasing a strong commitment to advancing cancer therapies and life sciences. With a robust background that includes previous roles as CEO of Nykode Therapeutics and EpiTherapeutics, and as Chairman of DANSK BIOTEK, Bonde possesses extensive experience in company formation and strategy. Educational credentials include a PhD in Chemistry from the Technical University of Denmark and advanced studies in Foreign Trade Economy and board leadership at Copenhagen Business School.